Mylan has launched its generic version of GlaxoSmithKline’s respiratory blockbuster, Advair, at a 70% discount compared with the original drug. Cheaper competition to off-patent Advair has been ...

A suit against Novartis and Vitaris by Henrietta Lacks’ estate hinges on questions about the morality and legality of using ...

Viatris (VTRS) stock surges after Q3 earnings beat expectations with strong revenue growth and optimistic revenue outlook for ...

Mylan’s Copaxone (glatiramer) generic hits Teva where it hurts as it has been approved at both the daily 20mg dose, or the 40mg thrice weekly dose that most patients have switched to.

A new focus on dermatology, ophthalmology, and gastroenterology will pave ways for many untapped opportunities that Viatris can utilize with its scale and manufacturing power. We believe Viatris is in ...

Pharmaceutical company Viatris (VTRS 13.52%) reported third-quarter 2024 financial results on Thursday, Nov. 7, that topped ...

Well, that was fast. It took Gov. Jim Justice all of one day after winning a seat in the U.S. Senate to play an exclusive game of political nepotism, appointing his wife, Cathy, to a nine-year term on ...

Heritage is ponying up $10 million while Apotex is set to pay $39.1 million over the companies’ alleged roles in a sweeping ...

We may not be the first wave launcher in the US, but we have plans." Natco and Mylan have also collaborated on the ...

The patent office decision would allow Mylan immediately to return to the market across Europe. The generic product is now ...

A comparative minnow, Torrent Pharmaceuticals, backed by a clutch of private equity players, also made a surprise bid but ...

Stuart Williams, chief legal officer for Mylan Pharmaceuticals, insists that the FDA decisions violate the Hatch-Waxman Act, and a court challenge seems likely. There's little doubt that the FDA ...